Table 1.

Microarray comparison of whole blood from sarcoidosis subjects at baseline and healthy controls

Phenotype	Subjects	Controls	Probesets
All	164	45	990
Lung	108	45	1197
Skin	39	45	684
Combined	17	45	1651

Microarray data generated from whole blood from sarcoidosis subjects prior to administration of study drug were compared to those generated from health controls. This comparison was repeated for each of four groups of subjects: all sarcoidosis subjects (All), subjects with the lung phenotype (Lung), subjects with the skin phenotype (Skin) and subjects with the combined phenotype (Combined). Subjects with the combined phenotype were not included in the lung or skin phenotype groups as they were in the original clinical study [8]. Probesets significantly different between each sarcoidosis phenotype and control were defined as those meeting a fold‐change cut‐off of 1·5, a corrected P‐value cut‐off of 0·05 and an LS mean cut‐off of 5. The numbers of subjects in each group are also shown.